

Bart L Haagmans

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/584421/publications.pdf](https://exaly.com/author-pdf/584421/publications.pdf)

Version: 2024-02-01

259
papers

43,958
citations

5727

83
h-index

2734

192
g-index

328
all docs

328
docs citations

328
times ranked

74909
citing authors

#	ARTICLE	IF	CITATIONS
1	Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in <i>in vivo</i> models. <i>MSphere</i> , 2024, 9, .	3.1	2
2	Juvenile Hormone Involved in the Defensive Behaviors of Soldiers in Termite <i>Reticulitermes aculabialis</i> . <i>Insects</i> , 2024, 15, 130.	2.3	0
3	Generalized Walsh Transform Sequency-Domain-Based Match Filtering for Electromagnetic Flowmeter Signal Measurement. <i>IEEE Sensors Journal</i> , 2024, 24, 10203-10220.	4.8	0
4	Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models. <i>Nature Communications</i> , 2024, 15, .	13.2	0
5	Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters. <i>Nature Communications</i> , 2024, 15, .	13.2	3
6	Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera. <i>Npj Vaccines</i> , 2024, 9, .	6.0	1
7	Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. <i>Nature Medicine</i> , 2023, 29, 270-278.	30.1	137
8	Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands. <i>Viruses</i> , 2023, 15, 212.	3.4	0
9	Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndromeâ€“Coronavirus Spike Protein. <i>Journal of Infectious Diseases</i> , 2023, 228, 586-590.	3.9	9
10	Intestinal Tropism of a Betacoronavirus (<i>Merbecovirus</i>) in <i>Nathusius</i> â€™s Pipistrelle Bat (<i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>)	3.5	3
11	Mpx virus infects and injures human kidney organoids, but responding to antiviral treatment. <i>Cell Discovery</i> , 2023, 9, .	6.9	4
12	The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells. <i>Life Science Alliance</i> , 2023, 6, e202201837.	2.9	5
13	Search for new phenomena in multi-body invariant masses in events with at least one isolated lepton and two jets using $\sqrt{s} = 13$ TeV protonâ€“proton collision data collected by the ATLAS detector. <i>Journal of High Energy Physics</i> , 2023, 2023, .	4.8	3
14	SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models. <i>Journal of Virology</i> , 2023, 97, .	3.5	12
15	SARS-CoV-2 ORF8 accessory protein is a virulence factor. <i>MBio</i> , 2023, 14, .	4.4	5
16	Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface. <i>PLoS Pathogens</i> , 2023, 19, e1011571.	4.1	8
17	Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry. <i>Antiviral Research</i> , 2023, 220, 105743.	4.2	1
18	Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients. <i>Vaccines</i> , 2023, 11, 1851.	4.5	0

#	ARTICLE	IF	CITATIONS
19	Interferon-Î±2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. <i>Journal of Clinical Immunology</i> , 2022, 42, 232-239.	3.8	30
20	Design and Licensure of an American Cord Blood Bank. , 2022, , 301-338.		0
21	Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands. <i>Emerging Microbes and Infections</i> , 2022, 11, 91-94.	6.6	11
22	SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. <i>Cell Research</i> , 2022, 32, 322-324.	12.2	161
23	Middle East respiratory syndrome coronavirus infection in camelids. <i>Veterinary Pathology</i> , 2022, 59, 546-555.	2.0	7
24	Divergent SARS-CoV-2 Omicron-â€œreactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	13.1	374
25	Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets. <i>MBio</i> , 2022, 13, e0383121.	4.4	6
26	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	36.2	128
27	Spreading of SARS-CoV-2 from hamsters to humans. <i>Lancet, The</i> , 2022, 399, 1027-1028.	12.1	12
28	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns. <i>PLoS Pathogens</i> , 2022, 18, e1010340.	4.1	16
29	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	29.2	516
30	Methods for fighting emerging pathogens. <i>Nature Methods</i> , 2022, , .	19.6	1
31	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. <i>Science Immunology</i> , 2022, 7, eabp9312.	13.1	42
32	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	30.1	54
33	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. <i>Nature Communications</i> , 2022, 13, .	13.2	79
34	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. <i>MBio</i> , 2022, 13, .	4.4	9
35	Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids. <i>EBioMedicine</i> , 2022, 81, 104132.	6.0	10
36	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. <i>Emerging Microbes and Infections</i> , 2022, 11, 1778-1786.	6.6	7

#	ARTICLE	IF	CITATIONS
37	Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. <i>Nature Communications</i> , 2022, 13, .	13.2	10
38	Deformation Properties of Rubberized Engineered Cementitious Composites Using Response Surface Methodology. <i>Iranian Journal of Science and Technology - Transactions of Civil Engineering</i> , 2021, 45, 729-740.	1.9	19
39	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <i>PLoS Pathogens</i> , 2021, 17, e1009282.	4.1	44
40	To determine the effect of long-term antiepileptic drug on the serum folate and vitamin B12 among epileptic patients. <i>Scientific Reports</i> , 2021, 11, 4393.	3.4	6
41	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	27.8	164
42	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. <i>Nature Communications</i> , 2021, 12, 1715.	13.2	149
43	Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation. <i>ELife</i> , 2021, 10, .	5.9	82
44	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021, 51, 1774-1784.	3.3	34
45	High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 1512-1521.	3.9	54
46	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3189.	13.2	144
47	Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. <i>MSphere</i> , 2021, 6, .	3.1	17
48	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	13.1	478
49	Advancing lung organoids for COVID-19 research. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	41
50	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021, 223, 2020-2028.	3.9	34
51	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.6	71
52	Science, not speculation, is essential to determine how SARS-CoV-2 reached humans. <i>Lancet, The</i> , 2021, 398, 209-211.	12.1	18
53	The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues. <i>Viruses</i> , 2021, 13, 1673.	3.4	31
54	Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	56

#	ARTICLE	IF	CITATIONS
55	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. <i>Nature Communications</i> , 2021, 12, 5498.	13.2	60
56	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	30.1	188
57	Animal models of SARS-CoV-2 transmission. <i>Current Opinion in Virology</i> , 2021, 50, 8-16.	5.6	28
58	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. <i>One Health</i> , 2021, 13, 100313.	3.5	32
59	An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. <i>EMBO Journal</i> , 2021, 40, e105912.	8.2	163
60	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). <i>Nature Communications</i> , 2021, 12, 267.	13.2	645
61	Susceptibility of rabbits to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2021, 10, 1-7.	6.6	142
62	SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. <i>ELife</i> , 2021, 10, .	5.9	121
63	Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021. <i>Biologicals</i> , 2021, 74, 10-15.	1.4	2
64	Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens. <i>PLoS ONE</i> , 2021, 16, e0259165.	2.5	31
65	Assessment to the Antifungal Effects in vitro and the Ocular Pharmacokinetics of Solid-Lipid Nanoparticle in Rabbits. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 7847-7857.	6.5	23
66	Analyzing dispersion properties of photonic crystal waveguides with hole and ring like lattice by introducing systematic shift and twist. <i>Optical and Quantum Electronics</i> , 2021, 53, 1.	3.3	2
67	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	36.2	745
68	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. <i>Eurosurveillance</i> , 2020, 25, .	7.4	6,101
69	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. <i>RMD Open</i> , 2020, 6, e001323.	4.4	2
70	How the COVID-19 pandemic highlights the necessity of animal research. <i>Current Biology</i> , 2020, 30, R1014-R1018.	4.0	30
71	Assessing the extent of SARS-CoV-2 circulation through serological studies. <i>Nature Medicine</i> , 2020, 26, 1171-1172.	30.1	44
72	How the COVID-19 pandemic highlights the necessity of animal research. <i>Current Biology</i> , 2020, 30, 4328.	4.0	12

#	ARTICLE	IF	CITATIONS
73	A human monoclonal antibody blocking SARS-CoV-2 infection. <i>Nature Communications</i> , 2020, 11, 2251.	13.2	980
74	Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. <i>Emerging Microbes and Infections</i> , 2020, 9, 1080-1091.	6.6	31
75	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	20.9	1,142
76	Severe Acute Respiratory Syndrome Coronavirus 2~Specific Antibody Responses in Coronavirus Disease Patients. <i>Emerging Infectious Diseases</i> , 2020, 26, 1478-1488.	4.4	1,429
77	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020, 11, 3436.	13.2	336
78	SARS-CoV-2 is transmitted via contact and via the air between ferrets. <i>Nature Communications</i> , 2020, 11, 3496.	13.2	413
79	Enzymatic versatility and thermostability of a new aryl-alcohol oxidase from <i>Thermothelomyces thermophilus</i> M77. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129681.	2.5	13
80	The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. <i>Nature Microbiology</i> , 2020, 5, 536-544.	13.1	6,091
81	Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. <i>Lancet, The</i> , 2020, 395, e42-e43.	12.1	191
82	SARS-CoV-2 productively infects human gut enterocytes. <i>Science</i> , 2020, 369, 50-54.	20.9	1,397
83	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. <i>EBioMedicine</i> , 2020, 55, 102743.	6.0	321
84	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. <i>Emerging Infectious Diseases</i> , 2020, 26, 1024-1027.	4.4	17
85	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 827-838.	8.9	136
86	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya. <i>Viruses</i> , 2020, 12, 396.	3.4	16
87	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. <i>Scientific Reports</i> , 2020, 10, 21894.	3.4	21
88	Phenotype and kinetics of SARS-CoV-2~specific T cells in COVID-19 patients with acute respiratory distress syndrome. <i>Science Immunology</i> , 2020, 5, .	13.1	879
89	Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.4	158
90	Authors~™ response: Plenty of coronaviruses but no SARS-CoV-2. <i>Eurosurveillance</i> , 2020, 25, .	7.4	1

#	ARTICLE	IF	CITATIONS
91	ADAR1: "Editor-in-Chief" of Cytoplasmic Innate Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1763.	4.9	152
92	Failure to detect MERS-CoV RNA in urine of naturally infected dromedary camels. <i>Zoonoses and Public Health</i> , 2019, 66, 437-438.	2.2	11
93	Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. <i>Emerging Microbes and Infections</i> , 2019, 8, 1593-1603.	6.6	31
94	Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. <i>Emerging Infectious Diseases</i> , 2019, 25, 1868-1877.	4.4	81
95	Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors. <i>Journal of Virology</i> , 2019, 93, .	3.5	34
96	Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits. <i>Viruses</i> , 2019, 11, 381.	3.4	10
97	Host Determinants of MERS-CoV Transmission and Pathogenesis. <i>Viruses</i> , 2019, 11, 280.	3.4	61
98	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. <i>Emerging Microbes and Infections</i> , 2019, 8, 516-530.	6.6	104
99	362. Hepatitis C Virus (HCV) Co-Infection in Women Living with Human Immunodeficiency Virus (HIV) in Northwest Louisiana. <i>Open Forum Infectious Diseases</i> , 2019, 6, S189-S190.	0.9	0
100	MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 2333-2335.	4.4	21
101	Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. <i>Scientific Reports</i> , 2019, 9, 18892.	3.4	21
102	Technical note: A simple method for retrieval of dust aerosol optical depth with polarized reflectance over oceans. <i>Atmospheric Chemistry and Physics</i> , 2019, 19, 15583-15586.	5.0	4
103	Dank. , 2019, , 527-528.		0
104	Unpredictable Nature of Environment on Nitrogen Supply and Demand. <i>Agronomy Journal</i> , 2019, 111, 2786-2791.	1.9	29
105	Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas. <i>Transboundary and Emerging Diseases</i> , 2019, 66, 831-841.	3.0	18
106	The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. <i>Swiss Medical Weekly</i> , 2019, 149, w20059.	1.5	4
107	DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 45-53.	5.7	92
108	Intuitionistic Fuzzy Power Aggregation Operator Based on Entropy and Its Application in Decision Making. <i>International Journal of Intelligent Systems</i> , 2018, 33, 49-67.	5.8	95

#	ARTICLE	IF	CITATIONS
109	Multihospital Outbreak of a Middle East Respiratory Syndrome Coronavirus Deletion Variant, Jordan: A Molecular, Serologic, and Epidemiologic Investigation. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy095.	0.9	20
110	Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4. <i>Scientific Reports</i> , 2018, 8, 9778.	3.4	34
111	Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. <i>Science Advances</i> , 2018, 4, eaas9667.	10.9	71
112	Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. <i>One Health</i> , 2018, 5, 65-68.	3.5	41
113	MERS-coronavirus: From discovery to intervention. <i>One Health</i> , 2017, 3, 11-16.	3.5	46
114	Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia. <i>Journal of Medical Virology</i> , 2017, 89, 1300-1303.	5.0	10
115	Virus genomes reveal factors that spread and sustained the Ebola epidemic. <i>Nature</i> , 2017, 544, 309-315.	36.2	367
116	Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. <i>Current Opinion in Virology</i> , 2017, 23, 49-58.	5.6	61
117	Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013-2014: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 1702-1705.	3.9	36
118	1,25-Dihydroxyvitamin D3 up-regulates IL-34 expression in SH-SY5Y neural cells. <i>Innate Immunity</i> , 2017, 23, 584-591.	2.4	20
119	Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8508-E8517.	7.6	284
120	Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells. <i>MSphere</i> , 2017, 2, .	3.1	85
121	Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients. <i>Scientific Reports</i> , 2017, 7, 4688.	3.4	17
122	Tissue Distribution of the MERS-Coronavirus Receptor in Bats. <i>Scientific Reports</i> , 2017, 7, 1193.	3.4	36
123	A novel hepatitis B virus subgenotype D10 circulating in Ethiopia. <i>Journal of Viral Hepatitis</i> , 2017, 24, 163-173.	2.1	15
124	Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus. <i>Emerging Infectious Diseases</i> , 2017, 23, 232-240.	4.4	92
125	Genetic diversity of hepatitis C virus in Ethiopia. <i>PLoS ONE</i> , 2017, 12, e0179064.	2.5	15
126	Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 716-719.	4.4	38

#	ARTICLE	IF	CITATIONS
127	MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic. <i>Emerging Infectious Diseases</i> , 2016, 22, 1129-1131.	4.4	69
128	Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. <i>Journal of Medical Virology</i> , 2016, 88, 1035-1043.	5.0	18
129	Miscarriage Associated with Zika Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1002-1004.	30.1	147
130	Intrathecal CD4 ⁺ and CD8 ⁺ T cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. <i>European Journal of Immunology</i> , 2016, 46, 347-353.	3.3	11
131	Cross host transmission in the emergence of MERS coronavirus. <i>Current Opinion in Virology</i> , 2016, 16, 55-62.	5.6	75
132	Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. <i>Journal of Virology</i> , 2016, 90, 4394-4401.	3.5	77
133	Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels. <i>Journal of Virology</i> , 2016, 90, 4838-4842.	3.5	113
134	Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization. <i>Journal of General Virology</i> , 2016, 97, 2180-2186.	2.9	15
135	The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reverse transcription polymerase chain reaction. <i>OIE Revue Scientifique Et Technique</i> , 2016, 35, 905-911.	1.2	9
136	Bad Apples Spoil the Fun: Quantifying Cheating in Online Gaming. <i>Proceedings of the International AAAI Conference on Weblogs and Social Media</i> , 2016, 10, 496-505.	2.4	1
137	High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. <i>Infection Ecology and Epidemiology</i> , 2015, 5, 28305.	0.8	70
138	Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand. <i>Emerging Infectious Diseases</i> , 2015, 21, 384-384.	4.4	11
139	Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013-2014. <i>Emerging Infectious Diseases</i> , 2015, 21, 1422-1425.	4.4	68
140	Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009-2013. <i>Emerging Infectious Diseases</i> , 2015, 21, 1205-1208.	4.4	56
141	Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct. <i>Journal of Virology</i> , 2015, 89, 4809-4817.	3.5	38
142	Reliable typing of MERS-CoV variants with a small genome fragment. <i>Journal of Clinical Virology</i> , 2015, 64, 83-87.	3.4	23
143	Pathogenesis of Middle East respiratory syndrome coronavirus. <i>Journal of Pathology</i> , 2015, 235, 175-184.	4.5	130
144	ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells. <i>Journal of Virology</i> , 2015, 89, 4434-4448.	3.5	103

#	ARTICLE	IF	CITATIONS
145	Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits. <i>Journal of Virology</i> , 2015, 89, 6131-6135.	3.5	74
146	Identification of Protein Receptors for Coronaviruses by Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2015, 1282, 165-182.	0.0	12
147	Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015. <i>Eurosurveillance</i> , 2015, 20, .	7.4	14
148	Presence of Anti-Interferon Antibodies is Not Associated with Non-Response to Pegylated Interferon Treatment in Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2014, 19, 423-427.	1.0	2
149	Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units. <i>PLoS ONE</i> , 2014, 9, e105227.	2.5	21
150	Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner. <i>PLoS Pathogens</i> , 2014, 10, e1004502.	4.1	348
151	New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands. <i>Emerging Infectious Diseases</i> , 2014, 20, 1218-22.	4.4	87
152	Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa. <i>Emerging Infectious Diseases</i> , 2014, 20, 1370-1374.	4.4	169
153	Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014. <i>Emerging Infectious Diseases</i> , 2014, 20, 1339-42.	4.4	166
154	Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype 1 infected patients. <i>Journal of Medical Virology</i> , 2014, 86, 177-185.	5.0	3
155	Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. <i>Vaccine</i> , 2014, 32, 5975-5982.	4.0	123
156	Membrane ectopeptidases targeted by human coronaviruses. <i>Current Opinion in Virology</i> , 2014, 6, 55-60.	5.6	38
157	MERS: emergence of a novel human coronavirus. <i>Current Opinion in Virology</i> , 2014, 5, 58-62.	5.6	175
158	Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes. <i>Journal of Virology</i> , 2014, 88, 1399-1400.	3.5	15
159	Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 140-145.	8.9	581
160	Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3722-3730.	4.4	103
161	Novel divergent nidovirus in a python with pneumonia. <i>Journal of General Virology</i> , 2014, 95, 2480-2485.	2.9	41
162	Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2014, 88, 1834-1838.	3.5	145

#	ARTICLE	IF	CITATIONS
163	Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 528-532.	3.3	107
164	The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models. <i>Journal of Comparative Pathology</i> , 2014, 151, 83-112.	0.3	143
165	Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. <i>Eurosurveillance</i> , 2014, 19, .	7.4	140
166	Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa. <i>Emerging Infectious Diseases</i> , 2014, 20, .	4.4	5
167	Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 859-866.	8.9	625
168	The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies. <i>Journal of Virology</i> , 2013, 87, 9379-9383.	3.5	207
169	Spiking the MERS-coronavirus receptor. <i>Cell Research</i> , 2013, 23, 1069-1070.	12.2	23
170	Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies. <i>Journal of Virology</i> , 2013, 87, 11950-11954.	3.5	129
171	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13109-13113.	7.6	435
172	Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. <i>Journal of General Virology</i> , 2013, 94, 1206-1210.	2.9	79
173	Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. <i>Nature</i> , 2013, 495, 251-254.	36.2	1,773
174	MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- α treatment. <i>Journal of General Virology</i> , 2013, 94, 1749-1760.	2.9	317
175	Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010-2011. <i>Emerging Infectious Diseases</i> , 2013, 19, .	4.4	76
176	Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes. <i>Journal of Virology</i> , 2013, 87, 7758-7764.	3.5	102
177	T-Cell Tropism of Simian Varicella Virus during Primary Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003368.	4.1	46
178	Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross. <i>PLoS Pathogens</i> , 2013, 9, e1003196.	4.1	191
179	Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody. <i>Journal of Virology</i> , 2013, 87, 13892-13899.	3.5	85
180	Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA. <i>Journal of Clinical Microbiology</i> , 2013, 51, 238-242.	4.4	36

#	ARTICLE	IF	CITATIONS
181	Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. <i>Eurosurveillance</i> , 2013, 18, 20662.	7.4	175
182	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	2.5	12
183	The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters. <i>PLoS ONE</i> , 2013, 8, e69127.	2.5	116
184	Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer. <i>PLoS ONE</i> , 2013, 8, e69711.	2.5	16
185	Metagenomic Analysis of the Ferret Fecal Viral Flora. <i>PLoS ONE</i> , 2013, 8, e71595.	2.5	71
186	Continuous Interferon- β Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients. <i>Antiviral Therapy</i> , 2012, 17, 509-517.	1.0	3
187	Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice. <i>G3: Genes, Genomes, Genetics</i> , 2012, 2, 213-221.	1.9	80
188	Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines. <i>MBio</i> , 2012, 3, .	4.4	183
189	Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans. <i>MBio</i> , 2012, 3, .	4.4	780
190	Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces. <i>Journal of Virology</i> , 2012, 86, 2360-2365.	3.5	101
191	Picobirnaviruses in the Human Respiratory Tract. <i>Emerging Infectious Diseases</i> , 2012, 18, 1538-1539.	4.4	33
192	Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh. <i>Emerging Infectious Diseases</i> , 2012, 18, 1192-1195.	4.4	29
193	Novel Hepatitis E Virus in Ferrets, the Netherlands. <i>Emerging Infectious Diseases</i> , 2012, 18, 1369-1370.	4.4	162
194	Impact of Obesity on the Bioavailability of Peginterferon- α 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. <i>PLoS ONE</i> , 2012, 7, e37521.	2.5	19
195	Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. <i>Eurosurveillance</i> , 2012, 17, .	7.4	319
196	Enteric Coronavirus in Ferrets, the Netherlands. <i>Emerging Infectious Diseases</i> , 2011, 17, 1570-1.	4.4	18
197	Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species. <i>Journal of Virology</i> , 2011, 85, 4234-4245.	3.5	68
198	Twice-weekly pegylated interferon- α 2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. <i>Aids</i> , 2011, 25, 1179-1187.	2.2	17

#	ARTICLE	IF	CITATIONS
199	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	2.5	131
200	A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus. PLoS ONE, 2011, 6, e18995.	2.5	36
201	Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?. Clinical Infectious Diseases, 2010, 50, e22-e25.	5.7	2
202	Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates. PLoS Pathogens, 2010, 6, e1000756.	4.1	296
203	Pharmacodynamics of PEG-IFN- α -2a in HIV/HCV co-infected patients: Implications for treatment outcomes. Journal of Hepatology, 2010, 53, 460-467.	3.9	31
204	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon- α -2b/ribavirin combination therapy after 4 weeks of treatment. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	1.6	2
205	SARS. , 2009, , 671-683.		2
206	Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Aids, 2009, 23, 2439-2450.	2.2	18
207	Unraveling the Complexities of the Interferon Response During Sars-Cov Infection. Future Virology, 2009, 4, 71-78.	1.7	15
208	Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection. Journal of Virology, 2009, 83, 7062-7074.	3.5	158
209	The Application of Genomics to Emerging Zoonotic Viral Diseases. PLoS Pathogens, 2009, 5, e1000557.	4.1	49
210	Virogenomics: the virus- α host interaction revisited. Current Opinion in Microbiology, 2008, 11, 461-466.	5.2	7
211	ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. Journal of Clinical Virology, 2008, 42, 160-164.	3.4	12
212	DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN- α and TNF- α . Virus Research, 2008, 135, 64-71.	2.3	65
213	Complete genome analysis of hepatitis C virus subtypes 6t and 6u. Journal of General Virology, 2008, 89, 1276-1281.	2.9	19
214	Severe acute respiratory syndrome (SARS) vaccines. , 2008, , 1301-1306.		0
215	Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV- α Infected Macaques. PLoS Pathogens, 2007, 3, e112.	4.1	59
216	Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients. Journal of Virology, 2007, 81, 12496-12503.	3.5	47

#	ARTICLE	IF	CITATIONS
217	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	1.4	57
218	The emerging role of ACE2 in physiology and disease. <i>Journal of Pathology</i> , 2007, 212, 1-11.	4.5	387
219	Modelling of Early Viral Kinetics and Pegylated Interferon- α 2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 1285-1294.	1.0	9
220	Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon- α . <i>Gastroenterology</i> , 2006, 131, 1452-1462.	1.4	121
221	Interferon- β and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. <i>Virology</i> , 2006, 353, 474-481.	2.5	122
222	Coronaviruses and their therapy. <i>Antiviral Research</i> , 2006, 71, 397-403.	4.2	47
223	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. <i>Hepatology</i> , 2006, 44, 721-727.	8.1	65
224	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	8.1	193
225	Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3969-3974.	4.4	48
226	Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus. <i>Journal of Virology</i> , 2006, 80, 7569-7577.	3.5	132
227	Authors' Response to Hogan. <i>PLoS Medicine</i> , 2006, 3, e415.	8.4	0
228	Interferon (IFN)- α Inducible Protein-10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN- α 2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	3.9	202
229	Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C. <i>New England Journal of Medicine</i> , 2006, 354, 1323-1324.	30.1	44
230	Nonhuman Primate Models for SARS. <i>PLoS Medicine</i> , 2006, 3, e194.	8.4	25
231	Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer. <i>European Urology</i> , 2005, 48, 153-161.	5.0	33
232	Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses. <i>Vaccine</i> , 2005, 23, 1343-1350.	4.0	5
233	Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- γ . <i>Journal of General Virology</i> , 2004, 85, 795-803.	2.9	19
234	Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2004, 11, 342-348.	2.1	8

#	ARTICLE	IF	CITATIONS
235	Pegylated interferon- β protects type 1 pneumocytes against SARS coronavirus infection in macaques. <i>Nature Medicine</i> , 2004, 10, 290-293.	30.1	375
236	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. <i>Lancet</i> , The, 2004, 363, 2139-2141.	12.1	256
237	The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. <i>Virology</i> , 2003, 312, 395-406.	2.5	71
238	Comparative study of different methods to genotype hepatitis C virus type 6 variants. <i>Journal of Virological Methods</i> , 2003, 109, 195-201.	2.1	57
239	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , 2003, 110, 201-209.	2.1	162
240	SARS virus infection of cats and ferrets. <i>Nature</i> , 2003, 425, 915-915.	36.2	547
241	Rat testicular germ cells and Sertoli cells release different types of bioactive transforming growth factor beta in vitro. <i>Reproductive Biology and Endocrinology</i> , 2003, 1, 3.	3.4	17
242	Prostate cancer gene therapy: Preliminary clinical and pre-clinical results. <i>European Urology Supplements</i> , 2003, 2, 141.	0.5	0
243	Molecular epidemiology of gibbon hepatitis B virus transmission. <i>Journal of General Virology</i> , 2003, 84, 147-155.	2.9	30
244	Pretreatment Intrahepatic CD8+Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2003, 188, 1528-1532.	3.9	20
245	Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant. <i>Journal of Virology</i> , 2002, 76, 10540-10545.	3.5	26
246	DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2-3 patients treated with PEG-interferon-alfa-2a and ribavirin. <i>Journal of Hepatology</i> , 2002, 36, 121.	3.9	7
247	Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. <i>Journal of General Virology</i> , 2002, 83, 1-10.	2.9	44
248	A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection. <i>Veterinary Immunology and Immunopathology</i> , 2000, 74, 121-136.	1.2	39
249	Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D. <i>Vaccine</i> , 1999, 17, 1264-1271.	4.0	32
250	Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs. <i>Veterinary Immunology and Immunopathology</i> , 1998, 66, 113-126.	1.2	73
251	Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony. <i>Virology</i> , 1997, 234, 349-363.	2.5	128
252	Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. <i>Journal of Virology</i> , 1994, 68, 2297-2304.	3.5	52

#	ARTICLE	IF	CITATIONS
253	Suppression of rat cytomegalovirus replication by antibodies against gamma interferon. <i>Journal of Virology</i> , 1994, 68, 2305-2312.	3.5	23
254	Tumor necrosis factor \pm levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection. <i>Veterinary Immunology and Immunopathology</i> , 1992, 35, 61-69.	1.2	30
255	Pneumococcal conjugate vaccines. <i>Immunology Letters</i> , 1991, 30, 267-274.	2.7	30
256	Protection of Rats against Pseudorabies Virus Infection by γ -Interferon. <i>Experimental Biology and Medicine</i> , 1989, 192, 47-55.	2.4	5
257	Priloga za zelene prireditve: Primer prireditve Praznik kozjanskega jabolka. , 0, , .		0
258	An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. <i>Nature Medicine</i> , 0, , .	30.1	0
259	Advancing COVID-19 diagnostics: rapid detection of intact SARS-CoV-2 using viability RT-PCR assay. <i>Microbiology Spectrum</i> , 0, , .	3.0	0